T he patient is a 25-yearold man with a significant past psychiatric history of schizophrenia with catatonic features that was diagnosed during his first hospitalization for psychosis 28 months prior to this current presentation. He presented with his mother to the emergency department because of odd behaviors. His mother had found him lying on the grass in their yard, face down with his eyes closed, and he was not responsive to her vocal prompts. He flailed his arms in bizarre patterns, and was incontinent of urine. He then got up and began "marching" up and down the street in his urine-soaked clothes, with exaggerated movements (ie, legs stiff and arms swinging). No overtly psychotic symptoms were noted by the family prior to this presentation apart from being "cautious"-for example, he would look at the garbage, then around the room and over his shoulders, leave the room, and then come back to the room later, move the garbage a couple of feet, look around, and leave again. This type of behavior, apart from his "religious practices," interfered with his ability to maintain activities of daily living.
From the patient's point of view, life was normal and he felt that his parents were "looking for a reason to call the police." When his hospitalization (prior to this current presentation) for compulsory treatment ended, he discontinued his use of clozapine because it made him feel "less spacious."
Back at home, he withdrew from most activities of daily living to spend all of his time focusing on religion. He practiced "all major religions" and meditated all day by pacing, sometimes with his eyes closed. He was no longer able to maintain his full-time job as a technician. He was no longer involved in any social activities, but did talk to his parents daily. He would not shop, prepare meals, or do other activities that could interfere with his religious practice. He denied any hallucinations or paranoia, although he could feel "God's vibration" pulsate through him. He had no symptoms currently or in the past of mania or depression. He denied suicidal or homicidal ideation. He had no history of substance abuse.
Review of his history noted an initial trial of risperidone followed by a trial of olanzapine after his first hospitalization in an outpatient setting. Both of these medications treated symptoms well, but the patient self-discontinued due to side effects of emotional blunting and sedation. With discontinuation of olanzapine, his symptoms returned and he was readmitted and received compulsory treatment with clozapine. While taking clozapine, he made marked improvement in activities of daily living, employment, and communication with his family. The patient stopped taking clozapine the day his compulsory treatment order ended, and he subsequently decompensated, leading to the current presentation.
Aripiprazole was initiated during the current hospital admission as the patient felt this had the most tolerable side-effect profile. As an outpatient, rapport was established based on the patient's interest in philosophy and religion. During outpatient appointments with his provider, he participated in mindfulness-based 
Relapse of Schizophrenia

D I A G N O S I S
DISCUSSION
Adherence to medication is one of the best predictors of relapse of psychosis. 1 Stopping antipsychotic medication increased the rate of relapse nearly 5-fold compared with continued treatment in a 5-year observational study of patients with FEP. 2 The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 3 showed discontinuation rates for oral antipsychotics to be 74% at 18 months for chronic schizophrenia. The European First Episode Schizophrenia Trial (EUFEST) 4 showed discontinuation rates for oral psychotics of 42% at 12 months for first-episode schizophrenia.
The relationship between the patient and psychiatrist is one of the biggest predictors of adherence to medication (Boston Collaborative Study). 5 Continuity of care for FEP also predicts service engagement and improved patient outcomes. "In particular, those who enter an FEP program without family involvement and support as well as those who maintain persistent substance abuse are at higher risk of disengagement." 6 Observational studies demonstrate many benefits of long-acting injectable medications, such as reducing total number of days in the hospital and better functional outcomes. 7, 8 Long-acting injectable antipsychotics are not often prescribed in patients with FEP 9 despite high nonadherence rates for oral medications and concurrent relapse of psychosis 10 (this is likely due to stigma associated with long acting injectable medications, as they are often seen as treatment of last resort).
Relapse of psychosis is not solely about total number of days in the hospital and economic consequences. For the patient, it is a loss of sense of self autonomy and independent living. Patients often are not offered long-acting injectable medication due to negative attitudes by providers and patients. 11, 12 Long-acting injectable medications are effective in patients with FEP. 9 
CONCLUSION
This case highlights the importance of early identification of patients who would benefit from a multielement approach to adherence and service engagement. In this case, long-acting injectable aripiprazole led to adherence to medication with concurrent global improvement in outcomes.
Evidence supports using psychologic interventions as an adjunct to pharmacotherapy in patients with schizophrenia. 10 An integrative and holistic medicine approach led to an outstanding rapport in this patient. This open-minded and nonjudgmental approach to long-acting injectable medications along with shared decision-making led to their use in this patient. As the patient responded to medication, he was able to meaningfully engage in other elements of the program, which helped him to recover further, ultimately leading to employment and independent living. The participation of the family in the education and support course was also an essential element. Without the family's support the patient would not have made it to all of his appointments Evidence supports using psychologic interventions as an adjunct to pharmacotherapy in patients with schizophrenia.
case challenge for therapy and the long-acting injectable medication.
In conclusion, it is critical to identify patients who would benefit from a multielement approach to service engagement and a longacting injectable medication. The three pillars of recovery are psychologic engagement of the patient, pharmacotherapy, and family engagement. Clinicians often focus on medication alone, leaving out the person sitting in front of them and their families, and turn to longacting injectable medications as a disciplinary measure for nonadherence. The term "nonresponder" was often used with this patient until he was actually adherent to medication. The outcome is remarkable, and he is not the only patient who could benefit from such an approach.
